Summit Therapeutics Share Discussion Threads

[kirk 6] 15/4/2019 12:22

Can only buy 10k now at just under 33.5

[kirk 6] 15/4/2019 11:57

If it breaks 40p today then I reckon all resistance is broken and £1 wouldn't be unrealistic

[volsung] 15/4/2019 11:39

Bought a few more. Looks to be gaining traction

[chrisatrdg] 15/4/2019 09:21

RNS what it means:

Surely the presentation over the weekend must mean Buy now before it is too late I agree with Kirk6.

Edit: We have lift off - up 17.27% & all Buys (Buy 33.5)

[kirk 6] 15/4/2019 09:07

This should be over 40p shortly

[waterloo01] 15/4/2019 07:59

Hopefully they will also get some grant funding to take both these targets forward. Wellcome/Barda/CarbX?

[football] 15/4/2019 07:22

Should rename this company Phoenix has its Risen From The Ashes that many times

[kirk 6] 15/4/2019 07:20

Released .....Summit Therapeutics plc Summit Presents In Vivo Proof Of Concept Data For New Mechanism Antibiotics Targeting Enterobacteriac...Source: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Presented In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 -- DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model -- Potential in Lung, Bloodstream and Urinary Tract Infections -- Activity Shown Against Resistant and Non-Resistant Strains -- Enterobacteriaceae are Gram-Negative Bacteria that Cause a Large Number of Serious Infections Oxford, UK, and Cambridge, MA, US, 15 April 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29(th) European Congress of Clinical Microbiology & Infectious Diseases ('ECCMID') in Amsterdam. Enterobacteriaceae are a family of Gram-negative bacteria responsible for a large number of severe and often deadly infections. In the data presented, a DDS-04 series compound cured infection in a translationally-relevant animal model of urinary tract infection, one of the major sites for Enterobacteriaceae infection. Therapeutic concentrations of the DDS-04 compound were also observed in other major sites in the animal model where life-threatening Enterobacteriaceae infections occur, including the lungs and the bloodstream. "Patients with Enterobacteriaceae infections are increasingly at risk for poor outcomes due to the spread of antimicrobial resistance," said Dr David Roblin, President of R&D of Summit. "Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy. There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes." The DDS-04 series acts via LolCDE, a novel bacterial target. The LolCDE site of DDS-04 series activity is conserved in the majority of therapeutically important Enterobacteriaceae, resulting in targeted spectrum compounds. With its new mechanism of action, the DDS-04 series was rapidly bactericidal and highly potent across globally diverse Enterobacteriaceae strains in research studies, which included multi-drug resistant isolates. Importantly, the DDS-04 series also showed low propensity for resistance development and did not show cross-resistance with existing classes of antibiotics, suggesting that DDS-04 compounds have the potential to overcome known resistance mechanisms. This profile makes the DDS-04 series attractive for further development for the treatment of Enterobacteriaceae infections. "The DDS-04 series aligns with our antibiotic strategy. There is a clear opportunity to improve patient outcomes and a need for new mechanisms to deliver these improved outcomes and also to help address the spread of antimicrobial resistance," commented Mr Glyn Edwards, Chief Executive Officer of Summit. "We look forward to gathering further data to support the selection of a preclinical candidate from the DDS-04 series." A copy of the presentation is available in the Publications section of the Company's website: https://www.globenewswire.com/Tracker?data=zF4OB7j7d6pSYP5Hg971LbjESS33LaZG5ArPp_57zfxJy8rR-_zzVA-Fkbbkp1Nyg9i2Qyb3rtxtHtD-vGKTKHqK5XJl97UGupr75mg7wpY= www.summitplc.com. About Enterobacteriaceae Enterobacteriaceae are a family of Gram-negative bacteria responsible for severe and often deadly infections. They account for a significant fraction of cases across conditions, including complicated urinary tract infections, bloodstream infections and hospital-acquired pneumonias. Summit estimates there are more than 1 million infections in the US annually caused by Enterobacteriaceae across these three settings. Increasing resistance of Enterobacteriaceae has rendered many marketed antibiotics ineffective against these bacteria. Two of the most alarming antibiotic resistance trends are extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE). ESBL is an enzyme that allows bacteria to become resistant to a wide variety of penicillin and cephalosporin antibiotics. ESBL-producing Enterobacteriaceae account for an estimated 26,000 infections annually in the US with 1,700 deaths, according to the US Centers for Drug Control and Prevention ('CDC'). CRE are resistant to nearly all existing antibiotics, including carbapenems which are considered the antibiotics of last resort. CRE account for an estimated 9,000 infections per year in the US and 600 deaths, according to the CDC. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Michelle Avery (US office) [phone] Cairn Financial Advisers LLP (Nominated Adviser) Tel: [phone] Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: [phone] Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Bryan Garnier & Co Limited (Joint Broker) Tel: [phone] Phil Walker / Dominic Wilson MSL Group (US) Tel: [phone] mailto:[e-mail] Jon Siegal [e-mail] --------------------------------- Consilium Strategic Communications (UK) Tel: [phone] Mary-Jane Elliott / Sue Stuart / Jessica mailto:[e-mail] Hodgson / [e-mail] --------------------------------- Lindsey Neville Summit Forward-looking Statements Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, the therapeutic potential of the Company's product candidates, the potential commercialisation of the Company's product candidates, the sufficiency of the Company's cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company's Annual Report on Form 20-F for the fiscal year ended 31 January 2019. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. -END- (END) Dow Jones NewswiresApril 15, 2019 02:00 ET (06:00 GMT)Copyright (c) 2019 Dow Jones & Company, Inc.

[kirk 6] 14/4/2019 17:00

Thanks football seen this just now on smmt - great news roll on tomorrow

[football] 14/4/2019 16:51

nasdaq rns

[chrisatrdg] 14/4/2019 16:42

The RNS was out Sunday because sensitive data was released today even though the markets open Monday up until now the data has been embargoed.Looking forward to Monday hopefully there will be some momentum with the share price

[kirk 6] 14/4/2019 16:19

The main thing that could come out of this is more Government funding or even a partner! If this happens it's back to the glory days of £2 plus

[football] 14/4/2019 16:17

Why email on a Sunday? could it be news out tomorrow am

[waterloo01] 14/4/2019 16:07

Wonder what else might come out of the platform? Very early days though, but encouraging and will help them get noticed as they keep adding new disease areas

[kirk 6] 14/4/2019 16:00

Thanks Waterloo yes it's definitely new but surprised it's released on a Sunday? We could be in for some great times shortly

[chrisatrdg] 14/4/2019 15:56

Hi All - I do not understand the science but it 'looks good to me' & based on Glyn's tweet message to me he is clearly excited (see my edit above) we may even see a positive response to share price Monday.

[waterloo01] 14/4/2019 15:55

kirk 6 they also released it on twitter this afternoon. Separate from the AWG release

[kirk 6] 14/4/2019 15:42

This was issued Friday :Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology a...Source: PR Newswire (US)WASHINGTON, April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinical and research programs at the 29th annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) to be held April 13 - 16 in Amsterdam, Netherlands. ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases."AWG is excited that data from our member companies covering a broad spectrum of infectious disease topics will be presented at ECCMID 2019," said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer of Paratek Pharmaceuticals and Chairman of the AWG. "Representatives from AWG companies will be participating in over 70 different oral sessions and poster presentations, along with integrated symposiums and industry panel discussions, showcasing developments in antifungal, antibacterial, and non-traditional therapies. Their efforts represent our coalition's sustained commitment to antimicrobial innovation and our dedication to developing life-saving treatments for patients in need."The following AWG member companies will be presenting at ECCMID 2019: Amplyx Pharmaceuticals, Cidara Therapeutics, Contrafect Corporation, Entasis Therapeutics, Iterum Therapeutics, Melinta Therapeutics, Motif Bio, Nabriva Therapeutics, Paratek Pharmaceuticals, SCYNEXIS, Summit Therapeutics, and VenatoRx Pharmaceuticals.For more information on AWG member company presentations and access to specific abstracts, please visit: www.antimicrobialsworkinggroup.com/eccmid-2019/ About The Antimicrobials Working GroupAWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of fourteen antimicrobials companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc. (NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis Therapeutics Inc. (NASDAQ: ETTX), Iterum Therapeutics Ltd. (NASDAQ: ITRM), Melinta Therapeutics Inc. (NASDAQ: MLNT), Motif Bio PLC (AIM/NASDAQ: MTFB) , Nabriva Therapeutics US Inc. (NASDAQ: NBRV), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc. (NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM), and VenatoRx Pharmaceuticals, Inc.For more information, visit: www.antimicrobialsworkinggroup.orgAbout The Conafay GroupThe Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.For more information, visit: www.conafaygroup.com Cision View original content:SOURCE Antimicrobials Working Group (AWG)Copyright 2019 PR Newswire

[kirk 6] 14/4/2019 15:41

I've signed up and not got this via email?

[chrisatrdg] 14/4/2019 15:34

Hi waterloo01 - How significant is this posting as we know from the last presentation these posters have been kept under wraps & Glyn seemed excited as to what they were presenting? Regards.

Link for the report:



Edit: Glyn messaged me 4 hrs ago 'Big day today!'

[waterloo01] 14/4/2019 14:51

How unusual, a Sunday news release just in via email.

Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019


Summit Therapeutics plc
(‘Summit’; or the ‘Company’;)

Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019

DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model
Potential in Lung, Bloodstream and Urinary Tract Infections
Activity Shown Against Resistant and Non-Resistant Strains
Enterobacteriaceae are Gram-Negative Bacteria that Cause a Large Number of Serious Infections
Oxford, UK, and Cambridge, MA, US, 14 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29th European Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID’;) in Amsterdam.

Enterobacteriaceae are a family of Gram-negative bacteria responsible for a large number of severe and often deadly infections. In the data presented, a DDS-04 series compound cured infection in a translationally-relevant animal model of urinary tract infection, one of the major sites for Enterobacteriaceae infection. Therapeutic concentrations of the DDS-04 compound were also observed in other major sites in the animal model where life-threatening Enterobacteriaceae infections occur, including the lungs and the bloodstream.

“Patients with Enterobacteriaceae infections are increasingly at risk for poor outcomes due to the spread of antimicrobial resistance,” said Dr David Roblin, President of R&D of Summit. “Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy. There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.”

The DDS-04 series acts via LolCDE, a novel bacterial target. The LolCDE site of DDS-04 series activity is conserved in the majority of therapeutically important Enterobacteriaceae, resulting in targeted spectrum compounds. With its new mechanism of action, the DDS-04 series was rapidly bactericidal and highly potent across globally diverse Enterobacteriaceae strains in research studies, which included multi-drug resistant isolates. Importantly, the DDS-04 series also showed low propensity for resistance development and did not show cross-resistance with existing classes of antibiotics, suggesting that DDS-04 compounds have the potential to overcome known resistance mechanisms. This profile makes the DDS-04 series attractive for further development for the treatment of Enterobacteriaceae infections.

“The DDS-04 series aligns with our antibiotic strategy. There is a clear opportunity to improve patient outcomes and a need for new mechanisms to deliver these improved outcomes and also to help address the spread of antimicrobial resistance,” commented Mr Glyn Edwards, Chief Executive Officer of Summit. “We look forward to gathering further data to support the selection of a preclinical candidate from the DDS-04 series.”

A copy of the presentation is available in the Publications section of the Company’s website: www.summitplc.com.

About Enterobacteriaceae
Enterobacteriaceae are a family of Gram-negative bacteria responsible for severe and often deadly infections. They account for a significant fraction of cases across conditions, including complicated urinary tract infections, bloodstream infections and hospital-acquired pneumonias. Summit estimates there are more than 1 million infections in the US annually caused by Enterobacteriaceae across these three settings. Increasing resistance of Enterobacteriaceae has rendered many marketed antibiotics ineffective against these bacteria. Two of the most alarming antibiotic resistance trends are extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE). ESBL is an enzyme that allows bacteria to become resistant to a wide variety of penicillin and cephalosporin antibiotics. ESBL-producing Enterobacteriaceae account for an estimated 26,000 infections annually in the US with 1,700 deaths, according to the US Centers for Drug Control and Prevention (‘CDC’). CRE are resistant to nearly all existing antibiotics, including carbapenems which are considered the antibiotics of last resort. CRE account for an estimated 9,000 infections per year in the US and 600 deaths, according to the CDC.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

[kirk 6] 11/4/2019 10:58

2.1 over on the Nasdaq pre trade and 27p here - massive discrepancy

[multiplural] 08/4/2019 20:41

Waterloo, thank you for the link. I saw this already. My problem is that the company announced that a live link would be available, and it was not. Only after the event you could hear the replay. They should sharpen their investor relation effort considerably if the want to attract investors.
Not that any news was presented, but they should make the real time available when they announce it.

[chrisatrdg] 08/4/2019 17:59

Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
• Data to be Presented in Oral Session at ECCMID 2019



The above is currently under embargo but is going to be new & may shift the share price